Tivic Health Systems becomes Valion Bio but the real story lies in its biodefense pivot
Valion Bio’s pivot to biodefense and oncology could reshape biotech funding. Find out what this transformation means for investors and the industry.
Pharma & Biotech
Pharma & Biotech
FDA maintains constructive stance as Island Pharmaceuticals progresses Galidesivir clinical development
Island Pharmaceuticals Limited has confirmed that the United States Food and Drug Administration (FDA) continues to evaluate its most recent regulatory submission related to Galidesivir, the company’s clinical-stage antiviral candidate being advanced under the Animal Rule pathway. In correspondence dated 2 January 2026, the regulator informed the Australian biotech firm that additional time is required